Cargando…

Identification of a Recurrent STRN/ALK Fusion in Thyroid Carcinomas

Thyroid carcinoma is the most common endocrine malignant tumor and accounts for 1% of all new malignant diseases. Among all types and subtypes of thyroid cancers that have been described so far, papillary thyroid carcinoma is the most frequent. The standard management treatment of these tumors consi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pérot, Gaëlle, Soubeyran, Isabelle, Ribeiro, Agnès, Bonhomme, Benjamin, Savagner, Frédérique, Boutet-Bouzamondo, Nathalie, Hostein, Isabelle, Bonichon, Françoise, Godbert, Yann, Chibon, Frédéric
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3903624/ https://www.ncbi.nlm.nih.gov/pubmed/24475247 http://dx.doi.org/10.1371/journal.pone.0087170

Ejemplares similares

STRN-ALK, A Novel In-Frame Fusion With Response to Alectinib
por: Nagasaka, Misako, et al.
Publicado: (2020)

STRN-ALK Fusion–Positive Case of Breast Cancer With Response to Alectinib
por: Kelly, Andrew D., et al.
Publicado: (2021)

A Papillary Thyroid Microcarcinoma Revealed by a Single Bone Lesion with No Poor Prognostic Factors
por: Godbert, Yann, et al.
Publicado: (2013)

Case Report: Ensartinib for gastric epithelioid inflammatory myofibrosarcoma with STRN-ALK fusion
por: Li, XiaoQing, et al.
Publicado: (2023)

STRN-ALK Fusion in Lung Adenocarcinoma with Brain Metastasis Responded Well to Ensartinib: A Case Report
por: Zhang, Linlin, et al.
Publicado: (2022)

Remarkable response to alectinib for metastatic papillary thyroid cancer with STRN-ALK fusion: A case report
por: Zhu, Lucheng, et al.
Publicado: (2022)

Coexistence of a novel STRN-ALK, NBEA-ALK double-fusion in an ovarian malignant mesothelioma patient: a case report and review
por: Wu, Xiao, et al.
Publicado: (2023)

Case Report: Identification of Two Rare Fusions, PDK1-ALK and STRN-ALK, That Coexist in a Lung Adenocarcinoma Patient and the Response to Alectinib
por: Zeng, Hao, et al.
Publicado: (2021)

STRN-ALK Fusion in Lung Adenocarcinoma with Excellent Response Upon Alectinib Treatment: A Case Report and Literature Review
por: Su, Cuiyun, et al.
Publicado: (2020)

Evolution of BCL-2/IgH hybrid gene RNA expression during treatment of T(14;18)-bearing follicular lymphomas
por: Soubeyran, P, et al.
Publicado: (1999)

STRN-ALK Rearranged Malignant Peritoneal Mesothelioma With Dramatic Response Following Ceritinib Treatment
por: Rüschoff, Jan H., et al.
Publicado: (2019)

STRN-ALK Fusion in a Case of Malignant Peritoneal Mesothelioma: Mixed Response to Crizotinib, Mode of Resistance, and Brigatinib Sequential Therapy
por: Gerthofer, Valeria, et al.
Publicado: (2021)

Estrogen-Related Receptor Alpha Modulates Lactate Dehydrogenase Activity in Thyroid Tumors
por: Mirebeau-Prunier, Delphine, et al.
Publicado: (2013)

A Rare STRN-ALK Fusion in Lung Adenocarcinoma Identified Using Next-Generation Sequencing–Based Circulating Tumor DNA Profiling Exhibits Excellent Response to Crizotinib
por: Yang, Yan, et al.
Publicado: (2017)

Primary resistance to alectinib in a patient with STRN‐ALK‐positive non‐small cell lung cancer: A case report
por: Sun, Kunyan, et al.
Publicado: (2021)

STRN-ALK rearranged pediatric malignant peritoneal mesothelioma – Functional testing of 527 cancer drugs in patient-derived cancer cells
por: Murumägi, Astrid, et al.
Publicado: (2021)

Tetraploidization of Immortalized Myoblasts Induced by Cell Fusion Drives Myogenic Sarcoma Development with DMD Deletion
por: Merle, Candice, et al.
Publicado: (2020)

Case Report: A rare case of non-small cell lung cancer with STRN-ALK fusion in a patient in very poor condition treated with first-line ensartinib
por: Song, Guo-qiang, et al.
Publicado: (2023)

Durable Clinical Response to Larotrectinib in an Adolescent Patient With an Undifferentiated Sarcoma Harboring an STRN-NTRK2 Fusion
por: Wu, Lawrence W., et al.
Publicado: (2018)

Cell–cell fusion of mesenchymal cells with distinct differentiations triggers genomic and transcriptomic remodelling toward tumour aggressiveness
por: Delespaul, Lucile, et al.
Publicado: (2020)

Heterogeneous Mechanisms of Secondary Resistance and Clonal Selection in Sarcoma during Treatment with Nutlin
por: Laroche, Audrey, et al.
Publicado: (2015)

MED12 Alterations in Both Human Benign and Malignant Uterine Soft Tissue Tumors
por: Pérot, Gaëlle, et al.
Publicado: (2012)

Silencing of STRN4 suppresses the malignant characteristics of cancer cells
por: Wong, Meihong, et al.
Publicado: (2014)

Recurrent DMD Deletions Highlight Specific Role of Dp71 Isoform in Soft-Tissue Sarcomas
por: Mauduit, Olivier, et al.
Publicado: (2019)

Germinal GLT8D1, GATAD2A and SLC25A39 mutations in a patient with a glomangiopericytal tumor and five different sarcomas over a 10-year period
por: Beddok, Arnaud, et al.
Publicado: (2021)

Pro-oncogene Pokemon Promotes Prostate Cancer Progression by Inducing STRN4 Expression
por: Jiang, Fuquan, et al.
Publicado: (2019)

circStrn3 is involved in bone cancer pain regulation in a rat model
por: Zhang, Yiwen, et al.
Publicado: (2020)

Greatwall promotes cell transformation by hyperactivating AKT in human malignancies
por: Vera, Jorge, et al.
Publicado: (2015)

CMTR1-ALK: an ALK fusion in a patient with no response to ALK inhibitor crizotinib
por: Du, Xue, et al.
Publicado: (2018)

MicroRNA-873 inhibits colorectal cancer metastasis by targeting ELK1 and STRN4
por: Fan, Chuannan, et al.
Publicado: (2018)

STK25 enhances hepatocellular carcinoma progression through the STRN/AMPK/ACC1 pathway
por: Zhang, Yichao, et al.
Publicado: (2022)

Impact of chromosomal instability on colorectal cancer progression and outcome
por: Orsetti, Béatrice, et al.
Publicado: (2014)

Acquisition of cancer stem cell capacities after spontaneous cell fusion
por: Merle, Candice, et al.
Publicado: (2021)

Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants
por: Cha, Yoon Jin, et al.
Publicado: (2016)

SMPD3‐ALK: A novel ALK fusion gene in lung adenocarcinoma
por: Liang, Yuepei, et al.
Publicado: (2021)

Uterine mesenchymal tumors harboring ALK fusions and response to ALK-targeted therapy
por: Kyi, Chrisann, et al.
Publicado: (2021)

Sensitivity of eight types of ALK fusion variant to alectinib in ALK-transformed cells
por: Furugaki, Koh, et al.
Publicado: (2021)

Analysis of the Peritumoral Tissue Unveils Cellular Changes Associated with a High Risk of Recurrence
por: Michot, Audrey, et al.
Publicado: (2023)

Severe thyrotoxicosis in an infant revealing familial nonautoimmune hyperthyroidism with a novel (C672W) stimulating thyrotropin receptor germline mutation
por: Oliver‐Petit, Isabelle, et al.
Publicado: (2017)

Variation of hormonal receptor, pS2, c-erbB-2 and GSTpi contents in breast carcinomas under tamoxifen: a study of 74 cases.
por: Soubeyran, I., et al.
Publicado: (1996)

Cannot write session to /tmp/vufind_sessions/sess_rg76312sih9npajmg69nv9du5v